STAT Inhibitors – Pipeline Insight, 2020
This report can be delivered to the clients within 72 Hours
DelveInsight’s, “STAT Inhibitors – Pipeline Insight, 2020,” report provides comprehensive insights about 60+ companies and 60+ pipeline drugs based on STAT Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
STAT Inhibitors: Overview
Signal Transducer and Activator of Transcription (STAT) proteins are a family of cytoplasmic transcription factors consisting of 7 members, STAT1 to STAT6, including STAT5a and STAT5b. STAT proteins are thought to be ideal targets for anti-cancer therapy since cancer cells are more dependent on the STAT activity than their normal counterparts. Inhibitors targeting STAT3 and STAT5 have been developed. These included peptidomimetics, small molecule inhibitors and oligonucleotides.
STAT Inhibitors Emerging Drugs Chapters
This segment of the STAT Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
STAT Inhibitors Emerging Drugs
Further product details are provided in the report……..
STAT Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different STAT Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
STAT Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses STAT Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging STAT Inhibitors drugs.
Report Highlights
DelveInsight’s, “STAT Inhibitors – Pipeline Insight, 2020,” report provides comprehensive insights about 60+ companies and 60+ pipeline drugs based on STAT Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
STAT Inhibitors: Overview
Signal Transducer and Activator of Transcription (STAT) proteins are a family of cytoplasmic transcription factors consisting of 7 members, STAT1 to STAT6, including STAT5a and STAT5b. STAT proteins are thought to be ideal targets for anti-cancer therapy since cancer cells are more dependent on the STAT activity than their normal counterparts. Inhibitors targeting STAT3 and STAT5 have been developed. These included peptidomimetics, small molecule inhibitors and oligonucleotides.
STAT Inhibitors Emerging Drugs Chapters
This segment of the STAT Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
STAT Inhibitors Emerging Drugs
- SHR0302: Jiangsu Hengrui Medicine
- OPB-111077: Otsuka Pharmaceutica
- Niclosamide intramuscular depot: Daewoong Pharmaceutical
Further product details are provided in the report……..
STAT Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different STAT Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in STAT Inhibitors
- Phases
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Oral
- Parenteral
- Subcutaneous
- Topical.
- Molecule Type
- Gene therapies
- Small molecule
- Vaccines
- Polymers
- Peptides
- Monoclonal antibodies
- Product Type
STAT Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses STAT Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging STAT Inhibitors drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence STAT Inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- Reistone's oral JAK1 inhibitor, SHR0302, is a China developed molecule licensed-in from Jiangsu Hengrui Medicine Co Ltd (Hengrui).
- STAT Inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
- What are the current treatment options available based on the STAT Inhibitors?
- How many companies are developing therapies by working on STAT Inhibitors?
- What are the principal therapies developed by these companies in the industry?
- How many therapies are developed by each company for STAT Inhibitors to treat disease condition?
- How many emerging therapies are in early-stage, mid-stage, and late stage of development for STAT Inhibitors?
- Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other treatments?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the STAT Inhibitors therapies?
- Which are the dormant and discontinued products and the reasons for the same?
- What is the unmet need for current therapies developed based on this mechanism of action?
- What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for STAT Inhibitors and their status?
- What are the results of the clinical studies and their safety and efficacy?
- What are the key designations that have been granted for the emerging therapies for STAT Inhibitors?
- How many patents are granted and pending for the emerging therapies of STAT Inhibitors?
- Singh Biotechnology
- AndroScience Corporation
- Wyeth
- Astellas
- Dolthera
- Jiangsu Hengrui Medicine
- Otsuka Pharmaceutica
- Daewoong Pharmaceutical
- SBT 101
- ASC ST.Z1
- Research programme: STAT3 transcription factor inhibitors
- Research programme: STAT6 inhibitors
- AVT 02
- SHR0302
- OPB-111077
- Niclosamide intramuscular depot
Introduction
Executive Summary
STAT Inhibitors: Overview
Classification
Mechanism of Action
Structure
Application
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
STAT Inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
STAT Inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
STAT Inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
SHR0302: Jiangsu Hengrui Medicine
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
OPB-111077: Otsuka Pharmaceutica
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Niclosamide intramuscular depot: Daewoong Pharmaceutical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Inactive Products
Comparative Analysis
STAT Inhibitors Key Companies
STAT Inhibitors Key Products
STAT Inhibitors- Unmet Needs
STAT Inhibitors- Market Drivers and Barriers
STAT Inhibitors- Future Perspectives and Conclusion
STAT Inhibitors Analyst Views
STAT Inhibitors Key Companies
Appendix
Executive Summary
STAT Inhibitors: Overview
Classification
Mechanism of Action
Structure
Application
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
STAT Inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
STAT Inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
STAT Inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
SHR0302: Jiangsu Hengrui Medicine
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
OPB-111077: Otsuka Pharmaceutica
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Niclosamide intramuscular depot: Daewoong Pharmaceutical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Inactive Products
Comparative Analysis
STAT Inhibitors Key Companies
STAT Inhibitors Key Products
STAT Inhibitors- Unmet Needs
STAT Inhibitors- Market Drivers and Barriers
STAT Inhibitors- Future Perspectives and Conclusion
STAT Inhibitors Analyst Views
STAT Inhibitors Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for STAT Inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for STAT Inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for STAT Inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for STAT Inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
